Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3D-EX Assay for Predicting Anti-PD1/PDL1 Response in NSCLC
NCT03371992Phase 1Unknown
- Sponsor
- Nilogen Oncosystems
- Start
- Mar 2018
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in non-small cell lung cancer (NSCLC), sponsored by Nilogen Oncosystems. Primary endpoint: Evaluation of target lesions by RECIST. Status: unknown.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03371992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03371992.